Chad Costley, MD/MBA
Dr. Chad Costley serves as the President and Chief Executive Officer of BlueWillow Biologics. Prior to assuming the operational leadership of the company, he served on the Board for numerous years and has led investment rounds as the managing director of Waubascon Capital and Line Moon Ventures. Dr. Costley has 20 years of clinical practice experience and has advised and served on the Boards of Directors of several technology companies. He earned his MD at the University of Michigan where he also completed medical residency training. He holds a MBA with distinction from Emory University as a Woodruff Scholar.
Hugo Braun is a partner and co-founder of North Coast Technology Investors, a Michigan-based venture capital firm with over $100 million under management that focuses on early stage investments in IT, advanced materials and life sciences. Prior to North Coast, Hugo worked in San Francisco co-managing BankAmerica’s venture capital portfolio. Hugo holds an M.S. in Management from the Sloan School at MIT and a B.A. in Economics from Yale University.
Gary Costley, Ph.D.
Gary E. Costley, Ph.D., chairs the BlueWillow board. He is co-founder and managing director of C&G Capital and Management, LLC, which provides capital and executive management support to health, nutrition, and medical product companies. Previously, he served as Chairman and Chief Executive Officer of International Multifoods Corporation, President of Kellogg North America, and Dean of the Wake Forest University Babcock School of Business. He also currently serves on the Board of Directors of Prestige Brand Holdings, Inc.
Roger D’Orazio is currently the Dealer Principal of D’Orazio Ford and the owner of Dora LLC, a single member owned REIT. He previously owned and operated Collision Revision, CR Coatings, CR Car Rental, CR Towing and CR Trucking & Logistics, prior to their sale in 2014. Roger was the founding Director of First Community Bank and in 2004 was named an Ernst & Young Entrepreneur of the Year.
David M. Stout
David M. Stout has served as a top-level pharmaceutical executive, both nationally and internationally, for the past 30 years. His most recent position was President of Pharmaceutical Operations for GlaxoSmithKline Pharmaceuticals. In this capacity, he led all global commercial activities, global manufacturing, and all vaccine-related activities for the company, including research and development. Additionally, Mr. Stout directed the corporate pandemic flu preparedness program – an international effort that supports governments, health authorities, and company employees around the world in responding to a global influenza pandemic.
Prior to his tenure at GSK, Mr. Stout served as President of SmithKline Beecham’s North American pharmaceutical business, launching two major products and two sales force expansions. His pharmaceutical career began at Warner-Lambert Pharmaceutical Company and continued at Schering-Plough Corporation, where he served in numerous positions, including President of Schering Laboratories.
Phil Wilmington is vice chairman at Workday, and focuses on building and expanding relationships with global customers, prospective customers, and strategic business partners, in addition to helping mentor the next generation of Workday sales leaders. Previously, from 2015 to 2018, Phil served as co-president.
Phil has more than 30 years’ experience in the enterprise software industry, most of which has been in executive management and leading customer-focused field operations. Prior to joining Workday, Phil served as president and chief operating officer at Tidemark Systems. Before Tidemark, he was president and CEO at OutlookSoft. Phil also previously served as co-president at PeopleSoft and held senior leadership positions at TriNet and Tesseract.
Phil holds a bachelor’s degree in marketing and business administration from Bradley University, and is a former member of the University’s board of trustees.